


LISTING OF CLAIMS

1-90 (canceled)

91. (new) A compound of formula (I):



wherein


R_a and R_b together with the nitrogen to which they are attached form a 6 membered heterocycle optionally including up to 3 additional heteroatoms;

n is 0-4;

R_1 is hydrogen or halo;

one of R_2 and R_3 is G and the other is hydrogen or halo;

G is



L_3 is phenyl or naphthyl;

L_6 is C_{1-5} alkylene;

L_7 is C_{1-5} alkylene or absent;

R_7 is H, hydroxyl, halo, or C_{2-6} alkoxy or is absent where the carbon linking L_6 and L_7 participates in a double bond;

R_{10} is H, C_{1-8} alkyl, C_{3-8} alkenyl, C_{3-7} cycloalkyl, $(C_{3-7}$ cycloalkyl) C_{1-6} alkylene, $(C_{2-15}$ heterocyclyl) C_{1-6} alkylene, or (phenyl) C_{1-6} alkylene;

wherein each of the above alkyl, alkylene, alkenyl, alkenylene, alkynyl, alkynylene, heterocyclyl, cycloalkyl, and aryl groups may each be unsubstituted or substituted with between 1 and 3 substituents independently selected from halo, amino, nitro, hydroxyl, and C_{1-3} alkyl;

or a pharmaceutically acceptable salt thereof.

92. (new) A compound of claim 91, wherein NR_aR_b taken together form piperidyl or methylpiperidyl.

93. (new) A compound of claim 92, wherein NR_aR_b taken together form piperidyl.

94. (new) A compound of claim 91, wherein R_2 is G.

95. (new) A compound of claim 91, wherein R_3 is G.

96. (new) A compound of claim 91, wherein n is between 1 and 4, inclusive.

97. (new) A compound of claim 96, wherein n is 1.

98. (new) A compound of claim 91, wherein L_3 is phenylene.

99. (new) The compound 1-{3-[2'-(1-Isopropyl-piperidin-4-yl)-biphenyl-4-yloxy]-propyl}-piperidine.

100. (new) A pharmaceutical composition comprising a compound of claim 91 or 99 and a pharmaceutically acceptable excipient.

101. (new) A compound of claim 91 or 99, isotopically-labelled to be detectable by positron emission tomography or single-photon emission computed tomography.

102. (new) A method of inhibiting histamine H_3 receptor activity in a subject, comprising administering an effective amount of a compound of claim 91 or 99 to a subject in need of such inhibition of histamine H_3 receptor activity.

103. (new) A method of treating a subject having a disease or condition modulated by histamine H_3 receptor activity, comprising administering to the subject a therapeutically effective amount of a compound of claim 91 or 99.

104. (new) A method of claim 103, wherein said disease or condition is selected from the group consisting of sleep/wake disorders, arousal/vigilance disorders, migraine, asthma, dementia, mild cognitive impairment (pre-dementia), Alzheimer's disease, epilepsy, narcolepsy, eating disorders, motion sickness, vertigo, attention deficit hyperactivity disorders, learning disorders, memory retention disorders, schizophrenia, nasal congestion, allergic rhinitis, and upper airway allergic response.

105. (new) A method for treating a disease or condition modulated by at least one receptor selected from the histamine H_1 receptor and the histamine H_3 receptor, said method comprising

(a) administering to a subject in need thereof a jointly effective amount of a histamine H₁ receptor antagonist compound, and (b) administering to the subject a jointly effective amount of a compound of claim 91 or 99, said method providing a jointly therapeutically effective amount of said compounds.

106. (new) The method of claim 105 wherein the histamine H₁ receptor antagonist and the compound of claim 91 are present in the same dosage form.

107. (new) The method of claim 105 wherein the histamine H₁ receptor antagonist and the compound of claim 99 are present in the same dosage form.

108. (new) A method for treating diseases or conditions modulated by at least one receptor selected from the histamine H₂ receptor and the histamine H₃ receptor in a subject, comprising (a) administering to the subject in need thereof a jointly effective amount of a histamine H₂ receptor antagonist compound, and (b) administering to said subject a jointly effective amount of a compound of claim 91 or 99, said method providing a jointly therapeutically effective amount of said compounds.

109. (new) The method of claim 108 wherein the histamine H₂ receptor antagonist and the compound of claim 91 are present in the same dosage form.

110. (new) The method of claim 108 wherein the histamine H₂ receptor antagonist and the compound of claim 99 are present in the same dosage form.

111. (new) A method for treating one or more disorders or conditions selected from the group consisting of sleep/wake disorders, narcolepsy, and arousal/vigilance disorders, comprising administering to a subject in need thereof a therapeutically effective amount of a compound of claim 91 or 99.

112. (new) A method for treating attention deficit hyperactivity disorders (ADHD), comprising administering to a subject a therapeutically effective amount of a compound of claim 91 or 99.

113. (new) A method for treating one or more disorders or conditions selected from the group consisting of dementia, mild cognitive impairment (pre-dementia), cognitive dysfunction, schizophrenia, depression, manic disorders, bipolar disorders, and learning and memory disorders, comprising administering to a subject in need thereof a therapeutically effective amount of a compound of claim 91 or 99.

114. (new) A method for treating or preventing upper airway allergic response, nasal congestion, or allergic rhinitis, comprising administering to a subject in need thereof a therapeutically effective amount of a compound of claim 91 or 99.

115. (new) A method for studying disorders mediated by the histamine H₃ receptor, comprising using an ¹⁸F-labeled compound of claim 91 as a positron emission tomography (PET) molecular probe.